ArticleBMC immunology2026
Elevated CDYL expression in the peripheral blood of patients with rheumatoid arthritis.
Article in BMC immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundChromodomain Y-like protein (CDYL), a member of the CDY-related gene family, plays a pivotal role in nervous diseases, reproductive systems and tumors by chromatin remodeling and disrupting normal transcriptional regulation. However, the expression and biological functions of CDYL in rheumatoid arthritis (RA) remain unclear. This study aims to investigated the role of CDYL in the pathogenesis of RA.
methodsA cohort of 43 RA patients and 36 healthy subjects were included in the study. The transcript levels of CDYL, interleukin-17 A (IL-17 A) and IL-22 were detected by quantitative real-time PCR. Flow cytometry and Western blot were used to analyze the relationship between CDYL and Th17 cells. The GSE100191 dataset from the GEO database was downloaded to conduct a comprehensive bioinformatics analysis of the potential functions of CDYL. The interaction of CDYL and EZH2 and the effects of the EZH2 antagonist on Th17 cells were measured by Western blot.
resultsThe CDYL was highly expressed in the PBMCs derived from RA patients, exhibiting positive correlations with DAS28 score (r = 0.36, p < 0.0177) and serum anti-cyclic citrullinated peptide antibody titers (r = 0.4255, p = 0.004). Moreover, the transcript levels of CDYL were positively correlated with elevated IL-17 A levels (r = 0.5140, p < 0.001) and IL-22 (r = 0.4540, p = 0.002) levels in RA patients and the RA dataset. CDYL expression is markedly upregulated in Th17 cells, while the proportion of Th17 cells is increased in RA patients. Mechanistically, CDYL knockdown significantly inhibited Th17 differentiation in vitro, which suggests that CDYL is associated with and functionally contributes to the differentiation of Th17 cells.
conclusionsOur findings indicate that CDYL expression is associated with and promotes the differentiation of Th17 cells in RA patients and may be involved in the process of RA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.